- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04520932
Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors (RFANET)
Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Low Grade Pancreatic Neuroendocrine Tumors of Less Than 2cm in Size
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary objective of the study is to evaluate the efficacy of radiofrequency treatment of grade 1 NF-PNETS with a size less than or equal to 2cm.
Patients meeting the selection criteria will be included in the study after signing the consent. They will benefit from a RFA treatment consisting of 1 to 3 sessions depending on their response to the treatment. Patients will then be followed for 5 years in order to evaluate their response to treatment, their clinical evolution, their quality of life and any complications.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dominique GENRE, MD
- Phone Number: +33491223778
- Email: drci.up@ipc.unicancer.fr
Study Locations
-
-
-
Marseille, France, 13009
- Recruiting
- Institut Paoli Calmettes
-
Contact:
- GOUARNE Caroline, PhD
- Phone Number: + 33 4 91 22 37 78
- Email: drci.up@ipc.unicancer.fr
-
Contact:
- GENRE Dominique, MD
- Phone Number: + 33 4 91 22 37 78
- Email: drci.up@ipc.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;
- Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67<3%,
- Non-secretory lesion.
- Homogeneous HEE contrast taking;
- No positron emission tomography (PET) FDG binding to the pancreatic mass;
- Lesion <20mm on conventional imaging at 6 months monitoring;
- Age 18 to 80 years inclusive;
- Patient in good general condition, World Health Organization [0-1];
- Signed consent to participate;
- Affiliation to healthcare insurance system or beneficiary of this regimen.
Exclusion Criteria:
- Pregnant or likely to become pregnant (without effective contraception) or breastfeeding ;
- A person in an emergency situation or deprived of liberty or placed under the authority of a tutor.
- Life expectancy < 1 year;
- Severe hemostasis disorders;
- Pancreatic and/or biliary ductal dilation;
- Lesion considered to be adjacent to the pancreatic duct and/or bile duct;
- Node extension and/or metastatic disease;
- Patient being managed for another malignant lesion which is progressive or under treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RFA treatment efficacy
PNETs ablation by radiofrequency treatment (1 to 3 sessions)
|
RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment response
Time Frame: 1 year
|
Complete response rate to radiofrequency treatment defined by the absence of enhancement with the contrast agent and/or the disappearance of the lesion on imaging.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fabrice CAILLOL, MD, Paoli Calmettes Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Pancreatic Diseases
- Neoplasms
- Pancreatic Neoplasms
- Neuroendocrine Tumors
Other Study ID Numbers
- RFANET-IPC 2020-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumor Grade 1
-
Yusuf MendaNational Cancer Institute (NCI); Holden Comprehensive Cancer Center; Perspective...Active, not recruitingNeuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1United States
-
University of Roma La SapienzaRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1Italy
-
University Hospital, Basel, SwitzerlandUniversity Hospital, Zürich; University Hospital Freiburg; Krebsforschung Schweiz... and other collaboratorsRecruitingThyroid Cancer, Medullary | Neuroendocrine Tumor of the Lung Grade 1 and 2 | Neuroendocrine Tumor of the Thymus Grade 1 and 2 | Neuroendocrine Tumor GEP Grade 1-3Switzerland
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; Assign Data Management and Biostatistics GmbHCompletedNeuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditionsGermany
-
David BushnellNational Cancer Institute (NCI); Holden Comprehensive Cancer Center; Perspective...RecruitingNeuroendocrine Tumors | Neuroendocrine Tumor of the Lung | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1 | Neuroendocrine Tumor of PancreasUnited States
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); NovartisCompletedIntermediate Grade Lung Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Functional Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Duodenal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor | Nonfunctional Pancreatic Neuroendocrine... and other conditionsUnited States
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... and other collaboratorsNot yet recruitingNeuroendocrine Tumor Grade 3
-
Peking Union Medical College HospitalHarbin Medical University; The First Affiliated Hospital of Xiamen UniversityRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3China
-
Abramson Cancer Center at Penn MedicineRoswell Park Cancer Institute; CARTIRecruitingNeuroendocrine Tumors | Neuroendocrine Tumor Grade 2United States
Clinical Trials on Radiofrequency ablation
-
Assistance Publique - Hôpitaux de ParisTerminatedHepatocellular CancerFrance
-
Xijing HospitalUnknown
-
Oxford University Hospitals NHS TrustRoyal Bournemouth and Christchurch Hospitals NHS Foundation TrustCompleted
-
Allevio Pain Management ClinicRecruitingShoulder Pain Chronic | Faceto-genic Neck Pain | Faceto-genic HeadacheCanada
-
Southwest Hospital, ChinaCompleted
-
Mansoura UniversityUnknownChronic Knee OsteoarthritisEgypt
-
University of CalgaryRecruitingOsteoarthritis, KneeCanada
-
Assistance Publique - Hôpitaux de ParisCompletedHepatocellular CarcinomasFrance
-
Aalborg University HospitalOdense University Hospital; St. Antonius HospitalTerminatedParoxysmal Atrial Fibrillation.Netherlands, Denmark
-
Ziekenhuis Oost-LimburgBelgium Health Care Knowledge Centre; Klinische Epidemiologie en Medical Technology...RecruitingKnee Osteoarthritis | Chronic Knee Pain | Persistent Postsurgical PainBelgium, Netherlands